Dr. Demirci from Harvard Medical School joined the Canary Foundation to lead their technology development efforts. Dr. Demirci’s previous efforts have yielded a point-of-care microchip technology to detect ovarian cancer biomarkers (e.g., HE4) using a 10-minute microchip assay and a cell phone as the detector. Dr. Demirci will continue to innovate around point-of-care diagnostics, microfluidics assays and the development of technology platforms at the convergence of engineering, biology and materials science.